Table 3

Crude incidence rates and adjusted HR for breast cancer among glargine users compared with detemir users by ever use, duration of use, cumulative dose, and length of follow-up

UsersBreast cancersPY of follow-upCrude breast cancer incidence rate per 1,000 PY (95% CI)Unweighted HR (95% CI)Weighted HR (95% CI)
Ever use
 Glargine203,1594,170691,3426.03 (5.85–6.21)0.98 (0.92, 1.04)0.98 (0.92,1.05)
 Detemir67,0121,233198,7316.20 (5.86–6.55)RefRef
Duration of use (years)
 Glargine 0 to <3203,1593,675612,5566.00 (5.81–6.19)0.97 (0.90, 1.03)0.97 (0.90, 1.04)
 Detemir 0 to <367,0121,122179,8756.24 (5.87–6.60)RefRef
 Glargine 3 to <537,14339261,5926.36 (5.73–6.99)1.14 (0.90, 1.44)1.14 (0.90, 1.46)
 Detemir 3 to <59,8728715,3175.68 (4.49–6.87)RefRef
 Glargine ≥510,87510317,1945.99 (4.83–7.15)0.89 (0.57, 1.38)0.91 (0.57, 1.43)
 Detemir ≥52,510243,5396.78 (4.07–9.50)RefRef
Cumulative dose (units)
 Glargine 0 to <20,000203,1592,835475,0805.97 (5.75–6.19)0.96 (0.89, 1.04)0.97 (0.90–1.05)
 Detemir 0 to <20,00067,012882141,6636.23 (5.82–6.64)RefRef
 Glargine 20,000 to <60,00079,4941,014169,8175.97 (5.60–6.34)1.00 (0.87, 1.14)0.98 (0.85–1.13)
 Detemir 20,000 to <60,00023,55726643,5096.11 (5.38–6.85)RefRef
 Glargine ≥60,00021,31832146,4466.91 (6.16–7.67)1.13 (0.89, 1.45)1.12 (0.87–1.44)
 Detemir ≥60,0006,5358513,5586.27 (4.94–7.60)RefRef
Length of follow-up (years)
 Glargine 0 to <3203,1592,780447,5396.21 (5.98–6.44)1.00 (0.92, 1.08)1.00 (0.93, 1.08)
 Detemir 0 to <367,012871139,7296.23 (5.82–6.65)RefRef
 Glargine 3 to <598,328840143,5685.85 (5.46–6.25)0.96 (0.83, 1.11)0.96 (0.82, 1.11)
 Detemir 3 to <527,47322837,5326.07 (5.29–6.86)RefRef
 Glargine ≥549,515550100,2355.49 (5.03–5.95)0.88 (0.73, 1.07)0.90 (0.74, 1.09)
 Detemir ≥511,89113421,4696.24 (5.18–7.30)RefRef
  • Data are n unless otherwise indicated. Ref, reference.